| Identification | Back Directory | [Name]
Flesinoxan | [CAS]
98206-10-1 | [Synonyms]
FLESINOXAN
N-(2-(4-((2R)-2,3-Dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl)-1-piperazinyl)ethyl)-4-fluorobenzamide
N-[2-[4-[[(R)-2,3-Dihydro-2α-hydroxymethyl-1,4-benzodioxin]-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide
N-[2-[4-[[(S)-2,3-Dihydro-2β-hydroxymethyl-1,4-benzodioxin]-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide
Benzamide, N-[2-[4-[(2R)-2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluoro- | [Molecular Formula]
C22H26FN3O4 | [MDL Number]
MFCD00865870 | [MOL File]
98206-10-1.mol | [Molecular Weight]
415.46 |
| Chemical Properties | Back Directory | [alpha ]
D +26° (c = 1 in methanol) | [Boiling point ]
635.8±55.0 °C(Predicted) | [density ]
1.271±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 31.25 mg/mL (75.22 mM) | [form ]
Solid | [pka]
14.09±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Description]
Flesinoxan is a new heterobicyclic-aryl-piperazine, chemically different from buspirone-like compounds. In vitro, flesinoxan is a highly selective 5-HT1A receptor agonist and has much weaker affinity for α1-adrenergic, dopamine 2, and dopamine 3 receptors compared with buspirone (Duphar, unpublished data). The highest density of flesinoxan binding sites in brain is observed in the hippocampus, dentate gyrus, lateral septum, and entorrhinal cortex (Duphar, unpublished data). In several animal paradigms of anxiety, flesinoxan is more potent in reducing anxiety than are buspirone and ipsapirone (Duphar, unpublished data). Phase II studies have shown that flesinoxan is clearly effective in relieving symptoms of generalized anxiety disorder and better than placebo (Duphar, unpublished data). Generally, a low dose (0.4 mg) of flesinoxan is well tolerated. Higher doses (4.0 mg) are associated with treatment emergent adverse events, such as nausea, vomiting, nervousness, dizziness, and headache (Duphar, unpublished data). Currently, flesinoxan is under clinical development as a treatment both for generalized anxiety disorder and for major depressive disorder. | [Uses]
Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects[1][2][3]. | [Biological Activity]
Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects. | [in vivo]
Flesinoxan acts as a partial agonist at postsynaptic and as a full agonist at presynaptic 5-HT1A receptors. The capacity of Flesinoxan to antagonize the effect of 5-HT on CA3 pyramidal neurons was similar to that of 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT)[1].
The intravenous administration of Flesinoxan suppresses the firing activity of both CA3 pyramidal neurons and dorsal raphe 5-HT neurons. The acute brain penetration of [3H]Flesinoxan and [3H]8-OH-DPAT are determined. Nine minutes after intravenous administration, [3H]8-OH-DPAT reached significantly greater brain concentration than [3H]Flesinoxan[1].
Subcutaneous administration of Flesinoxan and 8-OH-DPAT produce a dose-dependent hypothermia. The Flesinoxan-induced hypothermia is significantly attenuated by prior administration of the non-selective 5-HT1A antagonist pindolol and the 5-HT1/2 antagonist methysergide. Similar degrees of hypothermia are achieved with 3 mg/kg of Flesinoxan and 0.5 mg/kg of 8-OH-DPAT. The maximal effect of Flesinoxan occurs 30 min later than that of 8-OH-DPAT and fades more slowly[1]. | [IC 50]
5-HT1A Receptor: 24 nM (EC50) | [storage]
Store at -20°C | [References]
[1] Hadrava V, et al. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology. 1995 Oct;34(10):1311-26. DOI:10.1016/0028-3908(95)00098-q
[2] Schoeffter P, et al. Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br J Pharmacol. 1988 Nov;95(3):975-85. DOI:10.1111/j.1476-5381.1988.tb11728.x
[3] Rodgers RJ, et al. Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan. Pharmacol Biochem Behav. 1994 Aug;48(4):959-63. DOI:10.1016/0091-3057(94)90205-4 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
| Company Name: |
Alfa Chemistry
|
| Tel: |
+1 (201) 478-8534 |
| Website: |
www.alfa-chemistry.com |
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|